Juárez-Olguín H, Sandoval-Ramírez E, Adrián Guillé-Pérez A

Language: Spanish
References: 21
Page: 23-30
PDF size: 43.79 Kb.

ABSTRACT

The route followed by drug after its administration is known as LADME. Such route refers to liberation, absorption, distribution, metabolism and excretion. It is important to know each part of the process because it has a close relation with effi cacy and toxicity of drugs. According with the route of administration used and the pharmaceutical presentation selected by the clinician, the drugs can reach and maintain their therapeutic purposes, which are defi ned by LADME. Minimal studies on LADME have been done in children, although recently they have increased. The purpose of this paper is to analyze the LADME route followed by drugs in children.

REFERENCES

1. Gibaldi M, Perrier D. Farmacocinética. Barcelona, España: Ed Reverté; 2004. p.5.

2. Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001.

3. Wagner JG. Pharmacokinetics for the Pharmaceutical Scientist, Lancaster, PA: Technomic Publishing Company, Inc; 1993.

4. Nahata MC. Evolution of pediatric clinical pharmacy. Ann Pharmacother 2006;40:1170-9.

5. Lesko MS, Epstein FM, Mitchel AA. Recent patterns of drug use in newborn intensive care. J Pediatr 1990;116: 985-90.

6. Gilman TI. Therapeutic drug monitoring in the neonate and pediatric age group: Problems and clinical pharmacokínetics. Clin Pharmacokinet 1990;19:1-10.

7. Carlos MA, Babyn PS, Marcon MA, Moore AM. Changes in gastric emptying in early postnatal life. J Pediatr 1997;130:931-937.

8. MacLeod MS, Radde Cl. Pediatric Pharmacology and Therapeutics. St Louis: Mosby; 1993.

9. Yaffe A. Pediatric Pharmacology Therapeutic Principles in Practice. New York: WB Saunders; 1992.

10. Maxwell MG. Principles of Paediatric Pharmacology. New York: Croom Heim; 1984.

11. MacLeod MS, Radde RC. Eds. Mechanism of Drug Absorption and their Development, Textbook of Clinical Pharmacology. Massachusetts: PSG Publishing Co. Littleton; 1985.

12. Capers ChC, Ward SE, Murphy EJ, Job LB, Land AP. Use of theophylline in neonates as an aid to ventilator weaning. Ther Drug Monit 1992;14:471-4.

13. Juárez Olguín H, Flores Pérez J, Lares Asseff I, Loredo Abdala A, Carvajal Rodríguez L. Comparative pharmacokinetics of ASA and its metabolitos in children suffering from autoimmune disease. Biopharma Drug Dispos 2004;25:1-7.

14. McNamara P, Alcorn J. Protein Binding Predictions in Infants. AAPS Pharm Sci 2002;4:1-8.

15. Suzuki Y, Mimaki T, Cox S. Phenytoin age-dose-concentration relationship in children. Ther Drug Monit 1994;16:145-50.

16. Hattis D, Ginsberg G, Sonawane B, et al. Differences in pharmacokinetics between children and adults—II. Children’s variability in drug elimination half-lifes and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal 2003;23:117–42.

17. Prober GCh, Stevenson KD, Benitz EW. The use of antibiotics neonates weighting less than 1200 grams. Pediatr lnfect Dis J 1990;9:111-21.

18. Lares Al, Lugo GG, Pérez GG, Pérez OB, Guillé PA, Juárez OH. Predicción bayesiana de las concentraciones séricas de cloranfenicol en niños con sepsis y desnutrición. Rev lnvest Clin 1999;51:159-65.

19. Rodríguez PC, Udaeta ME, González TJ, Juárez OH, Belmont GA. Con centraciones de teofi lina postdosis de impregnación y estudio farmacocinético en la quinta dosis de mantenimiento en recién nacidos. Bol Med Hosp lnfant Mex 1991;48:164-71.

20. Dipiro JT, Spruill WJ, Wade WE, Blouin RA. Concepts in Clinical Pharmacokinetics, American Society of Health-System Pharmacists 4 ed. 2005

21. McGinnity DF, Collington J, Austin RP, Riley RJ. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 2007;8:463-79.